Linked Life Data

19383431

Source:http://linkedlifedata.com/resource/pubmed/id/19383431

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-4-22
pubmed:abstractText
Cilostazol, an antiplatelet drug used to treat intermittent claudication, has been reported to offer neuroprotection and endothelial protection in animals with ischemic brain injury. Here, we evaluated the protection afforded by cilostazol against ischemic brain injury and hemorrhagic transformation. Mice subjected to a 2-h filamental middle cerebral artery (MCA) occlusion were treated with cilostazol (10mg/kg, intraperitoneally just after the occlusion) or with vehicle. Histological outcomes (infarct volume and hemorrhagic transformation) and Evans blue extravasation were assessed after reperfusion. Mean infarct volume, hemorrhagic transformation, and Evans blue extravasation were all significantly reduced in the cilostazol-treated group. Thus, cilostazol protected against ischemic brain injury and hemorrhagic transformation in mice subjected to transient focal cerebral ischemia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0304-3940
pubmed:author
pubmed:issnType
Print
pubmed:day
13
pubmed:volume
452
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
156-61
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage.
pubmed:affiliation
Department of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University, 5-6-1 Mitahora-higashi, Gifu 502-8585, Japan.
pubmed:publicationType
Journal Article